Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Novartis |
---|---|
Information provided by: | Novartis |
ClinicalTrials.gov Identifier: | NCT00367978 |
This study evaluated the efficacy and safety of amlodipine/benazepril compared with that of enalapril in the treatment of hypertension in African-American patients with type 2 diabetes.
Condition | Intervention | Phase |
---|---|---|
Hypertension |
Drug: Amlodipine/benazepril |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Active Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | A Randomized, Multicenter, Study to Determine the Efficacy and Safety of Amlodipine/Benazepril Hydrochloride Versus Enalapril in the Treatment of Hypertension in an African-American Population With Type 2 Diabetes |
Estimated Enrollment: | 269 |
Study Start Date: | December 2001 |
Ages Eligible for Study: | 18 Years to 80 Years |
Genders Eligible for Study: | Both |
Inclusion Criteria:
Exclusion Criteria:
United States, New Jersey | |
Novartis Pharmaceuticals Corporation | |
East Hanover, New Jersey, United States, 07936 |
Study Director: | Novartis Pharmaceuticals Corporation | Novartis Pharmaceuticals |
Study ID Numbers: | CCIB002FUS06 |
Study First Received: | August 23, 2006 |
Last Updated: | August 23, 2006 |
ClinicalTrials.gov Identifier: | NCT00367978 |
Health Authority: | United States: Food and Drug Administration |
Hypertension, diabetes, African-American, amlodipine/benazepril |
Metabolic Diseases Diabetes Mellitus Vascular Diseases Endocrine System Diseases Amlodipine Calcium, Dietary Enalapril |
Enalaprilat Diabetes Mellitus, Type 2 Benazepril Endocrinopathy Glucose Metabolism Disorders Metabolic disorder Hypertension |
Membrane Transport Modulators Vasodilator Agents Molecular Mechanisms of Pharmacological Action Therapeutic Uses Angiotensin-Converting Enzyme Inhibitors Calcium Channel Blockers |
Enzyme Inhibitors Cardiovascular Diseases Cardiovascular Agents Antihypertensive Agents Pharmacologic Actions Protease Inhibitors |